Overview

Part A: Radiolabel Study With GW786034 Part B: Single Dose of GW786034

Status:
Completed
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
To study the absorption, distribution, metabolism and excretion of GW786034, and the absorption of a single IV dose of GW786034
Phase:
Phase 1
Details
Lead Sponsor:
GlaxoSmithKline